Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Buy” by Brokerages

Vor Biopharma Inc. (NYSE:VOR) has earned an average rating of “Buy” from the seven ratings firms that are covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have covered the stock in the last year is $11.36.

VOR has been the topic of a number of recent analyst reports. Wedbush restated an “outperform” rating and set a $11.00 target price on shares of Vor Biopharma in a report on Monday, December 9th. Robert W. Baird dropped their target price on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. HC Wainwright reiterated a “buy” rating and set a $17.50 price target on shares of Vor Biopharma in a report on Tuesday, December 10th. Finally, JMP Securities restated a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a research note on Tuesday, December 10th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in shares of Vor Biopharma in the 4th quarter valued at about $33,000. Rosalind Advisors Inc. bought a new stake in Vor Biopharma in the third quarter valued at approximately $54,000. Virtu Financial LLC acquired a new stake in Vor Biopharma during the 4th quarter valued at approximately $60,000. XTX Topco Ltd bought a new position in Vor Biopharma during the 4th quarter worth approximately $80,000. Finally, Trustees of Columbia University in the City of New York acquired a new position in shares of Vor Biopharma in the 4th quarter worth approximately $102,000. 97.29% of the stock is owned by institutional investors.

Vor Biopharma Stock Performance

NYSE VOR opened at $0.99 on Friday. Vor Biopharma has a 52 week low of $0.63 and a 52 week high of $2.43. The stock’s 50 day moving average price is $1.33 and its two-hundred day moving average price is $1.01. The stock has a market capitalization of $67.64 million, a price-to-earnings ratio of -0.60 and a beta of -0.40.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.